Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Pfizer Inc (PFE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 201,640,704
  • Shares Outstanding, K 5,955,130
  • Annual Sales, $ 52,824 M
  • Annual Income, $ 7,215 M
  • 36-Month Beta 0.98
  • Price/Sales 3.82
  • Price/Cash Flow 10.01
  • Price/Book 3.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.47 +1.34%
on 04/21/17
34.52 -1.74%
on 04/05/17
-0.24 (-0.70%)
since 03/28/17
3-Month
30.93 +9.67%
on 01/31/17
34.75 -2.39%
on 03/02/17
+2.50 (+7.96%)
since 01/27/17
52-Week
29.83 +13.71%
on 11/03/16
37.39 -9.28%
on 08/01/16
+1.01 (+3.07%)
since 04/28/16

Most Recent Stories

More News
Vertex (VRTX) Q1 Earnings Top, CF Products Sales Strong

Vertex Pharmaceuticals Incorporated (VRTX) reported first-quarter 2017 earnings per share of 13 cents (including the impact of stock-based compensation expense), which beat the Zacks Consensus Estimate...

CNCE : 15.87 (-0.75%)
VRTX : 118.30 (+0.75%)
PFE : 33.92 (+0.18%)
SNY : 47.30 (+0.83%)
Should You Buy Pfizer (PFE) Ahead of Earnings?

Pfizer (PFE) is seeing encouraging earnings estimate revision activity as of late and carries a favorable rank, positioning the company for a likely beat this season.

PFE : 33.92 (+0.18%)
Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More

Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.

MRK : 62.33 (-0.40%)
LLY : 82.06 (+0.90%)
NVS : 77.03 (-0.04%)
PFE : 33.92 (+0.18%)
GSK : 40.90 (+0.29%)
SNY : 47.30 (+0.83%)
BMY : 56.05 (+0.68%)
Pfizer Hosts Annual Meeting of Shareholders

The board of directors of Pfizer Inc. today declared a 32-cent second-quarter 2017 dividend on the company's common stock, payable June 1, 2017, to shareholders of record at the close of...

PFE : 33.92 (+0.18%)
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View

Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.

CORT : 9.54 (+2.14%)
MRK : 62.33 (-0.40%)
PFE : 33.92 (+0.18%)
BMY : 56.05 (+0.68%)
InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury

Research effort will use InSphero 3D InSight(TM) Human Liver Microtissues to develop novel assays to predict and evaluate certain mechanisms that cause drug-induced liver injury (DILI)

PFE : 33.92 (+0.18%)
InSphero Announces Agreement with Pfizer to Develop Novel Assays for Predicting Drug-induced Liver Injury

Research effort will use InSphero 3D InSight(TM) Human Liver Microtissues to develop novel assays to predict and evaluate certain mechanisms that cause drug-induced liver injury (DILI)

PFE : 33.92 (+0.18%)
Pfizer's Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer

Pfizer Inc. today announced that its investigational next-generation ALK/ROS1 tyrosine kinase inhibitor, lorlatinib, was granted Breakthrough Therapy designation from the U.S. Food and Drug...

PFE : 33.92 (+0.18%)
Pfizer (PFE) Q1 Earnings: Will it Pull Off a Surprise?

Pfizer, Inc. (PFE) will report first-quarter 2017 earnings on May 2, before market open. Last quarter, the company delivered a negative earnings surprise of 6.0%.

JNJ : 123.47 (-0.22%)
GILD : 68.55 (-0.04%)
AMGN : 163.32 (+0.37%)
PFE : 33.92 (+0.18%)
22nd Century Accepted to Present Proprietary Smoking Cessation Product at BIOCHINA Partnering Forum in Zhuhai, China

22nd Century Group, Inc. (NYSE MKT:XXII), a plant biotechnology company that is focused on tobacco harm reduction and cannabis research, announced today that James Vail, the Company's ...

AZN : 30.25 (-1.98%)
NVO : 38.68 (-0.26%)
XXII : 1.40 (+2.19%)
PFE : 33.92 (+0.18%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional...

See More

Support & Resistance

2nd Resistance Point 34.06
1st Resistance Point 33.99
Last Price 33.92
1st Support Level 33.80
2nd Support Level 33.68

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.